Monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with bortezomib

Franziska Grundmann1, Marco Witthus1, Heike Göbel2, Tuelay Kisner1, Rainer Siewert3, Thomas Benzing1,4 and Christine E. Kurschat1,4

1Department II of Internal Medicine, University of Cologne, Cologne, Germany, 2Department of Pathology, University of Cologne, Cologne, Germany, 3KfH Renal Center, Bergisch Gladbach, Germany and 4Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

Correspondence and offprint requests to: Christine E. Kurschat; E-mail: christine.kurschat@uk-koeln.de

Abstract
Extracapillary-proliferative glomerulonephritis is a rare complication of multiple myeloma. Partial remission of kidney involvement with cyclophosphamide therapy has previously been described. We report the case of a 60-year-old male patient diagnosed with rapidly progressive glomerulonephritis associated with IgG kappa monoclonal gammopathy. His kidney biopsy revealed pauci-immune extracapillary-proliferative glomerulonephritis without cryoglobulinaemia. Treatment with the proteasome inhibitor bortezomib induced rapid clinical and histological remission of his kidney disease. The patient’s renal function remained stable on bortezomib maintenance therapy. Our findings suggest that bortezomib is a promising therapeutic approach to ameliorate severe kidney damage in monoclonal gammopathy- and myeloma-associated pauci-immune extracapillary-proliferative glomerulonephritis.

Keywords: bortezomib; glomerulonephritis; MGRS; MGUS; multiple myeloma

Background
Renal manifestations of multiple myeloma are clinically and histologically diverse. The most common form of renal involvement, accounting for 33 to >60% of cases, is cast nephropathy characterized by an overabundance of toxic light chains in the tubular system. Light-chain deposition disease, primary amyloidosis, often complicated by nephrotic syndrome, proximal and distal tubular dysfunction, renal vein thrombosis due to hyperviscosity or type 1 cryoglobulinaemia are less commonly seen. Rapidly progressive glomerulonephritis is an unusual complication of multiple myeloma that has rarely been reported in the literature [1–5]. It is characterized by severe glomerular damage often involving >50% of the glomeruli in a renal biopsy [6]. Due to the associated rapid decline of renal function, often within weeks, prompt initiation of therapy is crucial to prevent additional damage. In general, the most common cause is pauci-immune glomerulonephritis with a mean age at presentation of 60 years [6–8]. This form of extracapillary-proliferative glomerulonephritis is closely correlated with circulating pathogenic anti-neutrophil cytoplasmic antibodies (ANCAs) in 80–90% of patients [8]. Immune complex-mediated glomerulonephritis and anti-glomerular basement membrane nephritis are less frequently diagnosed in this setting. Standard treatment of extracapillary-proliferative glomerulonephritis includes induction therapy with cyclophosphamide and steroids. In severe kidney and pulmonary disease, plasmapheresis to remove circulating antibodies may be beneficial. Mycophenolate mofetil or azathioprine is usually employed for maintenance immunosuppression. Rituximab as a B-cell-depleting therapy has also been successfully used [9, 10].

In multiple myeloma, bortezomib therapy in combination with dexamethasone recently became a first-line therapy for patients with myeloma-induced renal insufficiency [11]. Several studies documented a significant improvement in kidney function, usually within the initial two to three cycles of treatment [12].

We report a case of monoclonal gammopathy-associated pauci-immune extracapillary-proliferative glomerulonephritis successfully treated with the proteasome inhibitor bortezomib.

Case report
A 60-year-old male was referred to our department in April 2011 by his nephrologist due to an increase in his
A new renal biopsy was performed, again showing pauci-immune extracapillary-proliferative glomerulonephritis (4 of 10 crescents) with mild interstitial fibrosis. In this biopsy, there was also no evidence of classical myeloma-associated kidney disease. Due to the relapse of rapidly progressive glomerulonephritis after cyclophosphamide therapy and leucopenia during azathioprine treatment, we decided to administer two doses of 1 g of rituximab i.v. within 4 weeks and maintained the patient on a reduced dose of azathioprine in combination with cyclosporine A [1, 10]. Unfortunately, the patient showed rapid deterioration of his renal function within the following 8 weeks to a serum creatinine level of 303.6 µmol/L (3.45 mg/dL), an increase of proteinuria to 9 g/g and an increase of haematuria. The serum kappa/lambda free light-chain ratio also increased to 9.1. Because of the underlying plasma cell dyscrasia and rapidly worsening kidney function, we decided to start the patient on the proteasome inhibitor bortezomib (1.3 mg/m² body surface i.v. on Days 1, 8, 15, 22) in combination with dexamethasone based on the treatment recommendations for multiple myeloma. After the first cycle of bortezomib/dexamethasone, serum creatinine decreased to 140.8 µmol/L (1.6 mg/dL), minimal proteinuria of 0.48 g/g, no haematuria and well-controlled hypertension. Maintenance therapy of monthly bortezomib was initiated, and the patient showed stable serum creatinine values as well as stable proteinuria with 8 months of follow-up.

**Discussion**

Glomerulonephritis with crescents, although rare, is a well-documented complication of multiple myeloma. This association was first described by Kaplan and Kaplan in 1970, presenting a 49-year-old patient with renal failure due to extracapillary-proliferative glomerulonephritis, nephrotic syndrome and an IgG paraprotein [13]. Meyrier et al. [2] described three cases of extracapillary-proliferative glomerulonephritis in which plasma cell dyscrasia was identified in two patients and Waldenstrom's macroglobulinaemia in one patient as the underlying cause of renal disease. Renal function was stabilized by melphalan and steroids in the first patient and by steroids in combination with plasmapheresis in the third patient. Rapidly progressive glomerulonephritis has also been reported in patients with primary and secondary amyloidosis [1, 4, 14, 15].

The presence of paraproteins without characteristics of multiple myeloma (hypercalcocaemia, anaemia, bone disease) is referred to as ‘monoclonal gammopathy of undetermined significance’ (MGUS). Recently, Leung et al. [16] suggested to introduce the term ‘monoclonal gammopathy of renal significance’ (MGRS) if renal damage is present in these patients.

In this report, we describe a patient with pauci-immune extracapillary-proliferative glomerulonephritis due to IgG kappa monoclonal gammopathy, in which...
bortezomib and dexamethasone treatment significantly improved his renal function. Therefore, this patient suffers from MGRS. Histologically, after bortezomib therapy, crescents were sclerosed, a mild interstitial fibrosis and tubular atrophy developed and proliferative glomerulonephritis was stopped. The improvement of renal function after treatment with bortezomib was very rapid, suggesting a direct effect of bortezomib on the proliferative and inflammatory glomerular lesions. Bortezomib is a highly selective inhibitor of the 26S proteasome. This drug is known to inhibit protein degradation especially in high-turnover tumour cells, interfering with cell-cycle regulation and cell proliferation [17]. Due to the rapid improvement of the patient’s kidney function, we hypothesize that bortezomib exerted its beneficial effects not only through a control of plasma cell proliferation and paraprotein secretion, but also through direct inhibition of cell proliferation in the kidney. In a mouse model of ANCA-associated necrotizing crescentic glomerulonephritis, bortezomib was able to prevent renal disease [18].

Interestingly, no additional hallmarks of myeloma-associated kidney involvement were present in this patient’s renal biopsy. Histologically, no deposition of light chains or protein casts was detected. There was also no evidence for amyloidosis. Crosthwaite et al. [4] recently described a patient with primary AL amyloidosis and IgG kappa multiple myeloma that developed rapidly progressive glomerulonephritis in the setting of renal amyloidosis. In this patient, bortezomib and dexamethasone treatment led to a decrease of paraproteinaemia, but one month after initiation of therapy his serum creatinine started to rise and he became dialysis-dependent, suggesting that bortezomib treatment might be less effective if renal amyloidosis is present.

In our patient, the diagnosis of his underlying disease was not made until the second episode of rapid deterioration of kidney function when a thorough workup revealed elevated serum IgG kappa light chains. The fact that monoclonal gammopathy was not discovered earlier indicates that this disease was not primarily taken into account as a cause for his progressive glomerulonephritis. Therefore, we suggest that monoclonal gammopathy and multiple myeloma should be ruled out, especially in patients with ANCA-negative rapidly progressive glomerulonephritis.

In summary, this case demonstrates that in pauci-immune extracapillary-proliferative glomerulonephritis, the presence of monoclonal gammopathy and multiple myeloma, although a rare differential diagnosis, should be considered. Bortezomib therapy is a promising therapeutic approach to reverse severe kidney damage in myeloma-associated pauci-immune extracapillary-proliferative glomerulonephritis.

Conflict of interest statement. None declared.

References

1. Schafernak KT, Chugh SS, Kanwar YS. Co-existent crescentic glomerulonephritis and renal amyloidosis: a case report and literature review. J Nephrol 2005; 18: 616–622
2. Meyrier A, Simon P, Mignon F et al. Rapidly progressive (‘crescentic’) glomerulonephritis and monoclonal gammopathies. Nephron 1984; 38: 156–162
3. Vedder AC, Weening JJ, Krediet RT. Intracapillary proliferative glomerulonephritis due to heavy chain deposition disease. Nephrol Dial Transplant 2004; 19: 1302–1304
4. Crosthwaite A, Skene A, Mount P. Rapidly progressive glomerulonephritis complicating primary AL amyloidosis and multiple myeloma. Nephrol Dial Transplant 2010; 25: 2786–2789
5. Moscoso-Solorzano GT, Madureira-Silva MV, Baldo C et al. Crescentic glomerulonephritis in IgA multiple myeloma: a case report. Nephron Extra 2011; 1: 69–72
6. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63: 1164–1177
7. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512–1523
8. Kambham N. Crescentic Glomerulonephritis: an update on pauci-immune and anti-GBM diseases. Adv Anat Pathol 2012; 19: 111–124
9. Niles J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clin Exp Immunol 2011; 164: 27–30
10. Stone JH, Merkel PA, Spero R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221–232
11. Kostritis E, Dimopoulos MA, Blåde J. Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective. Adv Chronic Kidney Dis 2012; 19: 312–323
12. Dimopoulos MA, Richardson PG, Schlag R et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27: 6086–6093
13. Kaplan NG, Kaplan KC. Monoclonal gammopathy, glomerulonephritis and the nephritic syndrome. Arch Intern Med 1970; 125: 696–700
14. Andreu FJ, Almirall J, Jurado I et al. Renal failure in a patient with two renal diseases: renal amyloidosis and rapidly progressive glomerulonephritis. Nephrol Dial Transplant 1997; 12: 341–343
15. Bernheim J, Bernheim J. The patient with two renal diseases: crescentic glomerulonephritis and renal AA amyloid. Nephrol Dial Transplant 1999; 14: 1315–1316
16. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292–4295
17. Bianchi G, Ghebrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma 2013; 54: 229–241
18. Bonitscho J, Schreiber A, Manz RA et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22: 336–348

Received for publication: 5.1.13; Accepted in revised form: 26.3.13